Cross-talk between tumors can affect responses to therapy
暂无分享,去创建一个
R. Schwendener | P. Darcy | P. Beavis | M. Kershaw | J. Westwood | Liza B. John | Carmen S. M. Yong | Christel Devaud | C. Yong | J. A. Westwood
[1] Jorge Joven,et al. CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile , 2014, The Journal of Immunology.
[2] Deepak Mittal,et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.
[3] E. Elinav,et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.
[4] R. Montironi,et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma , 2013, Cancer Immunology, Immunotherapy.
[5] F. Schuetz,et al. B cell-regulated immune responses in tumor models and cancer patients , 2013, Oncoimmunology.
[6] B. Lippitz,et al. Cytokine patterns in patients with cancer: a systematic review. , 2013, The Lancet. Oncology.
[7] H. Moch,et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma , 2013, Oncoimmunology.
[8] J. Hamilton,et al. Colony stimulating factors and myeloid cell biology in health and disease. , 2013, Trends in immunology.
[9] W. Linehan,et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. , 2012, The Journal of urology.
[10] N. Restifo,et al. Cellular constituents of immune escape within the tumor microenvironment. , 2012, Cancer research.
[11] L. Zitvogel,et al. Abscopal but desirable , 2012, Oncoimmunology.
[12] P. Watson,et al. CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.
[13] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[14] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[15] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[16] L. Coussens,et al. Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.
[17] Hong Peng,et al. Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.
[18] T. Wynn,et al. Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.
[19] R. Geffers,et al. Macrophages at the Fetal–Maternal Interface Express Markers of Alternative Activation and Are Induced by M-CSF and IL-10 , 2011, The Journal of Immunology.
[20] J. Tímár,et al. Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.
[21] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[22] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[23] Zhao-You Tang,et al. Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.
[24] R. Schwendener,et al. Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice , 2009, Clinical Cancer Research.
[25] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[27] Matthew J. Craig,et al. CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.
[28] S. Amini,et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[29] C. Yeh,et al. Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity1 , 2009, The Journal of Immunology.
[30] Paula D. Bos,et al. Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.
[31] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[32] T. Whiteside. The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.
[33] P. Allavena,et al. Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.
[34] P. Allavena,et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.
[35] K. Czene,et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Sica,et al. Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.
[37] L. Coussens,et al. Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.
[38] A. Poggi,et al. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells , 2006, Archivum Immunologiae et Therapiae Experimentalis.
[39] T. Whiteside,et al. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.
[40] E. Esplugues,et al. Title: Induction of Tumor Nk Cell Immunity by Anti-cd69 Antibody Therapy , 2022 .
[41] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Fosså,et al. Chemotherapy in metastatic renal cell cancer , 2005, World Journal of Urology.
[43] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[44] E. Esplugues,et al. Enhanced Antitumor Immunity in Mice Deficient in CD69 , 2003, The Journal of experimental medicine.
[45] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[46] S. Rosenberg,et al. Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based Therapy , 2001, Journal of immunotherapy.
[47] M. Loda,et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 , 2000, Nature.
[48] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[49] G. Murphy,et al. A murine renal cell carcinoma. , 1973, Journal of the National Cancer Institute.
[50] J. Flynn,et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] G. Kroemer,et al. 2012 Landes Bioscience. Do not distribute. Abscopal but desirable The contribution of immune responses to the efficacy of radiotherapy , 2012 .
[52] L. Coussens,et al. Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.